Haemodialysis-associated amyloidosis

Haemodialysis-associated amyloidosis is a form of systemic amyloidosis associated with chronic kidney failure.[1]

Haemodialysis-associated amyloidosis
SpecialtyEndocrinology 

Presentation

Long-term haemodialysis results in a gradual accumulation of β2 microglobulin, a serum protein, in the blood.[2] It accumulates because it is unable to cross the dialysis filter.

Affected individuals usually present after 5 years of dialysis rarely before that. The tendency of haemodialysis-associated amyloidosis is to be articular in general affecting the joints.

Diagnosis

Prevention

Low copper dialysis is theorized to prevent or delay onset.[3]

Management

See also

References
  1. Miyata T, Oda O, Inagi R, et al. (September 1993). "beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis". J. Clin. Invest. 92 (3): 1243–52. doi:10.1172/JCI116696. PMC 288264. PMID 8376584.
  2. Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 978-1-4160-2999-1.
  3. "BU Amyloid Treatment & Research Program". Archived from the original on 2008-07-20.
Classification
External resources


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.